Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Recruiting 6Completed 4

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Lymphoid 1Genitourinary 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Prostatic Neoplasms 1Neoplasm Metastasis 1Mucopolysaccharidosis I 1Hodgkin Disease 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Clinical Trials, Phase II as Topic × Clear all
NCT01171898 2026-05-11

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Aragon Pharmaceuticals, Inc.

Phase 1/2 Completed
127 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT03411161 2021-05-25

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Servier

Phase 1/2 Completed
22 enrolled
Breast

Breast Neoplasms, Mucopolysaccharidosis I, Triple Negative Breast Neoplasms

NCT01471847 2020-12-09

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Novartis

Phase 1 Completed
5 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01572519 2020-11-20

A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

Janssen Research & Development, LLC

Phase 1 Completed
21 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡